Published in Br J Pharmacol on September 01, 2011
The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol (2013) 1.70
New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res (2012) 0.94
The endocannabinoid system in prostate cancer. Nat Rev Urol (2011) 0.92
Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis (2013) 0.89
Apoptosis Induced by 13-S-hydroxyoctadecadienoic acid in the Breast Cancer Cell Lines, MCF-7 and MDA-MB-231. Iran J Basic Med Sci (2013) 0.81
Egr-1 contributes to IL-1-mediated down-regulation of peroxisome proliferator-activated receptor γ expression in human osteoarthritic chondrocytes. Arthritis Res Ther (2012) 0.80
In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA. PLoS One (2014) 0.79
The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes. BMC Cancer (2015) 0.79
Molecular mechanisms for age-associated mitochondrial deficiency in skeletal muscle. J Aging Res (2012) 0.78
Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival. Horm Cancer (2013) 0.78
Genetic variants of peroxisome proliferator-activated receptor δ are associated with gastric cancer. Dig Dis Sci (2013) 0.77
Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. PLoS One (2015) 0.77
PPARα Is Required for PPARδ Action in Regulation of Body Weight and Hepatic Steatosis in Mice. PPAR Res (2015) 0.77
HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity. Mol Endocrinol (2013) 0.77
Apoptosis Induced by 13-S-hydroxyoctadecadienoic acid in the Breast Cancer Cell Lines, MCF-7 and MDA-MB-231. Iran J Basic Med Sci (2013) 0.76
Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells. Iran J Basic Med Sci (2016) 0.75
Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway. Clin Transl Med (2017) 0.75
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
Adipogenesis and obesity: rounding out the big picture. Cell (1996) 5.15
Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A (2001) 3.58
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res (2006) 3.01
Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med (1998) 2.90
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest (1997) 2.73
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev (1996) 2.58
Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis (1997) 2.46
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 2.08
Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology (2008) 1.99
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med (2004) 1.89
Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res (2000) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol (1998) 1.65
PPARs in the brain. Biochim Biophys Acta (2007) 1.63
Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes (1998) 1.63
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat (2003) 1.60
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology (2007) 1.56
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun (2000) 1.52
Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer (2000) 1.47
Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene (2005) 1.40
Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett (1999) 1.35
SIRT1 is regulated by a PPAR{γ}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res (2010) 1.35
Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer (2008) 1.34
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J (2002) 1.33
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer (2003) 1.31
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res (2000) 1.27
Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol (2007) 1.26
Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol (1994) 1.24
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis (2005) 1.24
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis (2007) 1.23
Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis (2000) 1.21
Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol (1999) 1.20
Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol (2010) 1.19
PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun (2003) 1.18
The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci (2007) 1.18
Retracted Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. Am J Respir Cell Mol Biol (2008) 1.17
Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res (2006) 1.16
PPARgamma in monocytes: less pain, any gain? Cell (1998) 1.15
Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther (2009) 1.15
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol (2009) 1.14
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia (2005) 1.14
Retracted PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol (2008) 1.12
Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res (2005) 1.10
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol (2010) 1.10
Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila) (2008) 1.10
Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics (2007) 1.09
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther (2002) 1.08
Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene (2002) 1.07
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res (2005) 1.07
Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology (2001) 1.07
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer (2003) 1.07
Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res (2006) 1.05
Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett (2005) 1.05
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology (2010) 1.05
Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol (2008) 1.04
Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology (2003) 1.03
Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol (2005) 1.02
PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer (2008) 1.02
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery (2006) 1.02
Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut (2003) 1.01
Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res (2001) 1.01
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun (1999) 1.00
A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut (2002) 0.98
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology (2008) 0.98
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep (2007) 0.97
Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer (2002) 0.97
Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact (2010) 0.96
RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol (2006) 0.96
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res (2008) 0.95
Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol (2009) 0.95
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer (2007) 0.94
Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci (2002) 0.94
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology (2002) 0.94
Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. Int J Oncol (2007) 0.93
Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res (2009) 0.93
Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med (2008) 0.92
PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem (2009) 0.92
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes (2006) 0.92
Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol (2005) 0.92
Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ (2002) 0.90
Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. J Biomed Biotechnol (2004) 1.05
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation (2002) 1.00
Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha. Mech Ageing Dev (2002) 0.85
Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis. ScientificWorldJournal (2002) 0.79
Chronic kidney disease: pharmacological considerations for the dentist. J Am Dent Assoc (2010) 0.79
PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists. PPAR Res (2012) 0.79
Glucocorticoid-like effects of antihepatocarcinogen Rotenone are mediated via enhanced serum corticosterone levels: Molecular Fitting and Receptor Activation Studies. J Carcinog (2003) 0.78
Pantothenic acid: an organ-specific pro-oxidant vitamin. Brain and liver neuroprostane levels in rats fed a pantothenic acid-deficient diet. Adv Exp Med Biol (2002) 0.75
PPARs in Viral Disease. PPAR Res (2009) 0.75
Genetic Variation of PPARs. PPAR Res (2009) 0.75